Stoke Therapeutics Announces Alignment with Global Regulatory Agencies and Plans to Initiate a Phase 3 Study of Zorevunersen as Potentially the First Disease-Modifying Medicine for the Treatment of Dravet Syndrome

Published on January 7, 2025

Conference Call for Analysts and Investors Stoke management will host a webcast and conference call for analysts and investors on Tuesday,

Continue reading on website
Other news

Ashish Jain's 2025 Financial Market Overview: A Year of Challenges and Opportunities

January 7, 2025
Jain and Alieus Hedge FundAshish Jain is the visionary Founder and CEO of Alieus Hedge Fund, a globally recognized investment firm. Known

Covalon Announces Strong Fourth Quarter and Year End Fiscal 2024 Results

January 7, 2025
will also be available on www.covalon.com under Financials on the Investors tab.Financial PerformanceFor the three-month period ended